|
|
| |
These programs were planned and conducted by the corporate community in conjunction with the American Diabetes Association's 67th Annual Scientific Sessions. They provide attendees with additional educational/informational opportunities. Program content and product information are the sole responsibility of the organizers. |
 |
Evolution of Insulin Therapy
Jointly sponsored by Tulane University and CADRE
The FDA's approval of the first non-invasive insulin formulation is another important event in the history of insulin therapy. This program reviews the history and the body of evidence that supports insulin as the most fully tested and most reliably effective treatment for diabetes. It covers the evolution of increasingly sophisticated formulations of insulin, development of various regimens for clinical use, and some of the barriers and controversies which still limit the use of insulin therapy. The potential for inhaled insulin as a catalyst for further improvement of insulin therapy will be reviewed. |
 |
A Road Map for Managing Anemia in the Patient with Type 2 Diabetes and CKD
Sponsored by SCEPTERTM and supported by an educational grant from Ortho Biotech Products, L.P.
The American Diabetes Association (ADA) Standards of Care recommend that all patients with diabetes should have annual measurements of serum creatinine and estimated glomerular filtration rate (eGFR), regardless of the presence of albuminuria. Staging based on eGFR helps clinicians identify patients with chronic kidney disease (CKD) who should be screened for additional complications, such as anemia. About 50% of patients with diabetes and predialysis CKD have anemia, as defined by hemoglobin levels of ≤12 g/dL. Anemia, which is associated with decreased quality of life and reduced functional capacity, also contributes to renal decline and left ventricular hypertrophy (LVH).
Treatment of anemia with erythropoiesis stimulating agents (ESAs) can improve exercise tolerance, cognitive function, and quality of life, as well as prevent LVH progression in patients with CKD. Recent data provide important guidance on the optimal approach to anemia treatment with ESAs in order to maximize benefits and minimize risks. Early diagnosis, assessment, and management of CKD-related anemia in patients with type 2 diabetes mellitus (T2DM) are important and present significant challenges to the clinician. |
 |
The Role of Nuclear Receptors: Integrating the Science and Medicine of Bile Acid Metabolism
Supported through an educational grant from Daiichi Sankyo, Inc. and sponsored jointly by Insight Medical Communications Inc. and Medical Education Collaborative.
Through recent research, many new receptors and metabolic pathways that impact on the progression of type 2 diabetes have been discovered, and the number of therapeutic choices for treating patients with type 2 diabetes continues to increase. Despite this, a majority of patients with type 2 diabetes are not meeting targeted lipid or glycemic goals.
The gap between targeted and accomplished goals has serious implications for the reduction of diabetic complications, particularly cardiovascular disease. A currently available treatment option offers the potential to overcome these challenges. A novel strategy to achieve both lipid and glycemic goals is to incorporate bile acid sequestrants into existing diabetes treatment regimens. These agents exploit a unique metabolic pathway through the liver and intestine, which has the potential to bring both LDL-C and glucose levels closer to goal. As a result, the cardiovascular risk of patients may be reduced. |
|
